| Literature DB >> 33160187 |
Stephanie N Hudey1, Dennis K Ledford1, Juan Carlos Cardet2.
Abstract
Non-type 2 inflammation (Non-T2)-mediated asthma is difficult to define due to lack of signature biomarkers. It exists in the absence of T2-high or eosinophilic inflammation and includes neutrophilic and paucigranulocytic subtypes. Several cell types and cytokines, including Th1, Th17, IL-6, and IL-17, contribute to mechanisms of non-T2 asthma. Neutrophil extracellular traps (NETs) and inflammasome activation likely play a role in severe neutrophilic asthma. Several mechanisms lead to uncoupling of airway hyperresponsiveness and remodeling from airway inflammation in paucigranulocytic asthma. Recent research on transcriptomics and proteomics in non-T2 asthma is discussed in this review. Investigations of specific drug therapies for non-T2 asthma have been disappointing, and remain an important area for future clinical studies.Entities:
Year: 2020 PMID: 33160187 PMCID: PMC7852882 DOI: 10.1016/j.coi.2020.10.002
Source DB: PubMed Journal: Curr Opin Immunol ISSN: 0952-7915 Impact factor: 7.486